Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion

References

• Yuan TL, Cantley LC, PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27(41):5497-510; PMID:18794884; http://dx.doi.org/10.1038/onc.2008.245
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4(4):257-62; PMID:14585353; http://dx.doi.org/10.1016/S1535-6108(03)00248-4
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8(8):627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd2926
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13(2):140-56; PMID:24481312; http://dx.doi.org/10.1038/nrd4204
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012; 109(8):2718-23; PMID:21368164; http://dx.doi.org/10.1073/pnas.1018001108
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19(1):58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
   PubMed Web of Science ®Google Scholar
• Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30(22):2547-57; PMID:21278786; http://dx.doi.org/10.1038/onc.2010.626
   PubMed Web of Science ®Google Scholar
• Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, Lisanti S, Rampini P, Giroda M, Caino MC, et al. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst 2015; 107(3): PMID:25650317; http://dx.doi.org/10.1093/jnci/dju502
   PubMed Web of Science ®Google Scholar
• Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci U S A 2015; 112(28):8638-43; PMID:26124089
   PubMed Web of Science ®Google Scholar
• Manning, BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129(7):1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 2011; 12(1):30-42; PMID:21190521; http://dx.doi.org/10.2174/138920311795659407
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6(11):1122-8; PMID:15467718; http://dx.doi.org/10.1038/ncb1183
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14(14):1296-302; PMID:15268862; http://dx.doi.org/10.1016/j.cub.2004.06.054
   PubMed Web of Science ®Google Scholar
• Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O'Connell M, Jernigan D, Fatatis A, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 2013; 123(7):2907-20; PMID:23921130; http://dx.doi.org/10.1172/JCI67841
   PubMed Web of Science ®Google Scholar
• Wong PM, Puente C, Ganley IG, Jiang X. The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy 2013; 9(2):124-37; PMID:23295650; http://dx.doi.org/10.4161/auto.23323
   PubMed Web of Science ®Google Scholar
• Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, Lou HJ, Raveendra-Panickar D, Yang CC, Sheffler DJ, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 2015; 59(2):285-97; PMID:26118643; http://dx.doi.org/10.1016/j.molcel.2015.05.031
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8(4):210-21; PMID:21364524; http://dx.doi.org/10.1038/nrclinonc.2011.21
   PubMed Web of Science ®Google Scholar
• Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65(11):4929-38; PMID:15930315; http://dx.doi.org/10.1158/0008-5472.CAN-04-4458
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov 2015; 5(3):264-73; PMID:25542447; http://dx.doi.org/10.1158/2159-8290.CD-14-0293
   PubMed Web of Science ®Google Scholar
• Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18(6):892-901; PMID:22610277; http://dx.doi.org/10.1038/nm.2772
   PubMed Web of Science ®Google Scholar
• Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer 2014; 14(11):709-21; PMID:25342630; http://dx.doi.org/10.1038/nrc3803
   PubMed Web of Science ®Google Scholar
• Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012; 12(10):685-98; PMID:23001348; http://dx.doi.org/10.1038/nrc3365
   PubMed Web of Science ®Google Scholar
• Alirol E, Martinou JC. Mitochondria and cancer: is there a morphological connection? Oncogene 2006; 25(34):4706-16; PMID:16892084; http://dx.doi.org/10.1038/sj.onc.1209600
   PubMed Web of Science ®Google Scholar
• Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science 2012; 337(6098):1062-5; PMID:22936770; http://dx.doi.org/10.1126/science.1219855
   PubMed Web of Science ®Google Scholar
• Desai SP, Bhatia SN, Toner M, Irimia D. Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J 2013; 104(9):2077-88; PMID:23663851; http://dx.doi.org/10.1016/j.bpj.2013.03.025
   PubMed Web of Science ®Google Scholar
• Attanasio F, Caldieri G, Giacchetti G, van Horssen R, Wieringa B, Buccione R. Novel invadopodia components revealed by differential proteomic analysis. Eur J Cell Biol 2011; 90(2-3):115-27; PMID:20609496; http://dx.doi.org/10.1016/j.ejcb.2010.05.004
   PubMed Web of Science ®Google Scholar
• Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S. Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. PLoS One 2015; 10(3):e0122308; PMID:25822260; http://dx.doi.org/10.1371/journal.pone.0122308
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, Abel PW, Tu Y. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 2013; 32(40):4814-24; PMID:23128392; http://dx.doi.org/10.1038/onc.2012.494
   PubMed Web of Science ®Google Scholar
• Infante AS, Stein MS, Zhai Y, Borisy GG, Gundersen GG. Detyrosinated (Glu) microtubules are stabilized by an ATP-sensitive plus-end cap. J Cell Sci 2000; 113 (Pt 22):3907-19; PMID:11058078
   PubMed Web of Science ®Google Scholar
• Chen Y, Sheng ZH. Kinesin-1-syntaphilin coupling mediates activity-dependent regulation of axonal mitochondrial transport. J Cell Biol 2013; 202(2):351-64; PMID:23857772; http://dx.doi.org/10.1083/jcb.201302040
   PubMed Web of Science ®Google Scholar
• Yang X, Kovalenko OV, Tang W, Claas C, Stipp CS, Hemler ME. Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J Cell Biol 2004; 167(6):1231-40; PMID:15611341; http://dx.doi.org/10.1083/jcb.200404100
   PubMed Web of Science ®Google Scholar
• Wang, D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10(3):181-93; PMID:20168319; http://dx.doi.org/10.1038/nrc2809
   PubMed Web of Science ®Google Scholar
• Godoy JA, Arrázola MS, Ordenes D, Silva-Alvarez C, Braidy N, Inestrosa NC. Wnt-5a ligand modulates mitochondrial fission-fusion in rat hippocampal neurons. J Biol Chem 2014; 289(52):36179-93; PMID:25336659; http://dx.doi.org/10.1074/jbc.M114.557009
   PubMed Web of Science ®Google Scholar
• Hahn WS, Kuzmicic J, Burrill JS, Donoghue MA, Foncea R, Jensen MD, Lavandero S, Arriaga EA, Bernlohr DA. Proinflammatory cytokines differentially regulate adipocyte mitochondrial metabolism, oxidative stress, and dynamics. Am J Physiol Endocrinol Metab 2014; 306(9):E1033-45; PMID:24595304; http://dx.doi.org/10.1152/ajpendo.00422.2013
   PubMed Web of Science ®Google Scholar
• Ryu SW, Yoon J, Yim N, Choi K, Choi C. Downregulation of OPA3 is responsible for transforming growth factor-β-induced mitochondrial elongation and F-actin rearrangement in retinal pigment epithelial ARPE-19 cells. PLoS One 2013; 8(5):e63495; PMID:23658835; http://dx.doi.org/10.1371/journal.pone.0063495
   PubMed Web of Science ®Google Scholar
• Todd LR, Damin MN, Gomathinayagam R, Horn SR, Means AR, Sankar U. Growth factor erv1-like modulates Drp1 to preserve mitochondrial dynamics and function in mouse embryonic stem cells. Mol Biol Cell 2010; 21(7):1225-36; PMID:20147447; http://dx.doi.org/10.1091/mbc.E09-11-0937
   PubMed Web of Science ®Google Scholar
• Beck H, Flynn K, Lindenberg KS, Schwarz H, Bradke F, Di Giovanni S, Knöll B. Serum response factor (SRF)-cofilin-actin signaling axis modulates mitochondrial dynamics. Proc Natl Acad Sci U S A 2012; 109(38):E2523-32; PMID:22927399; http://dx.doi.org/10.1073/pnas.1208141109
   PubMed Web of Science ®Google Scholar
• Kim H, Scimia MC, Wilkinson D, Trelles RD, Wood MR, Bowtell D, Dillin A, Mercola M, Ronai ZA. Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. Mol Cell 2011; 44(4):532-44; PMID:22099302; http://dx.doi.org/10.1016/j.molcel.2011.08.045
   PubMed Web of Science ®Google Scholar
• Han XJ, Yang ZJ, Jiang LP, Wei YF, Liao MF, Qian Y, Li Y, Huang X, Wang JB, Xin HB, et al. Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. Int J Oncol 2015; 46(2):691-700; PMID:25434519
   PubMed Web of Science ®Google Scholar
• Li Y, Lim S, Hoffman D, Aspenstrom P, Federoff HJ, Rempe DA. HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport. J Cell Biol 2009; 185(6):1065-81; PMID:19528298; http://dx.doi.org/10.1083/jcb.200811033
   PubMed Web of Science ®Google Scholar
• Zanelli SA, Trimmer PA, Solenski NJ. Nitric oxide impairs mitochondrial movement in cortical neurons during hypoxia. J Neurochem 2006; 97(3):724-36; PMID:16606371; http://dx.doi.org/10.1111/j.1471-4159.2006.03767.x
   PubMed Web of Science ®Google Scholar
• Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci U S A 2011; 108(25):10190-5; PMID:21646527; http://dx.doi.org/10.1073/pnas.1107402108
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell 2008; 134(5):703-7; PMID:18775299; http://dx.doi.org/10.1016/j.cell.2008.08.021
   PubMed Web of Science ®Google Scholar
• Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010; 107(19):8788-93; PMID:20421486; http://dx.doi.org/10.1073/pnas.1003428107
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458(7239):762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823
   PubMed Web of Science ®Google Scholar
• Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013; 18(5):698-711; PMID:24206664; http://dx.doi.org/10.1016/j.cmet.2013.10.001
   PubMed Web of Science ®Google Scholar
• Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014; 514(7524):628-32; PMID:25119024; http://dx.doi.org/10.1038/nature13611
   PubMed Web of Science ®Google Scholar
• Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013; 23(6):811-25; PMID:23764003; http://dx.doi.org/10.1016/j.ccr.2013.05.003
   PubMed Web of Science ®Google Scholar
• Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun 2013; 4:2139; PMID:23842546; http://dx.doi.org/10.1038/ncomms3139
   PubMed Web of Science ®Google Scholar
• Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2015; 27(6):864-76; PMID:26058080; http://dx.doi.org/10.1016/j.ccell.2015.05.004
   PubMed Web of Science ®Google Scholar
• Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9(6):447-64; PMID:20467424; http://dx.doi.org/10.1038/nrd3137
   PubMed Web of Science ®Google Scholar
• Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L, Altieri DC, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 2009; 119(3):454-64; PMID:19229106; http://dx.doi.org/10.1172/JCI37613
   PubMed Web of Science ®Google Scholar
• Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007; 131(2):257-70; PMID:17956728; http://dx.doi.org/10.1016/j.cell.2007.08.028
   PubMed Web of Science ®Google Scholar
• Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 2012; 22(3):331-44; PMID:22975376; http://dx.doi.org/10.1016/j.ccr.2012.07.015
   PubMed Web of Science ®Google Scholar
• Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, Zhang J, Iyengar R, Jung CH, Suen DF, et al. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell 2011; 43(4):572-85; PMID:21855797; http://dx.doi.org/10.1016/j.molcel.2011.06.018
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross AH, Plescia J, Altieri DC. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest 2011; 121(4):1349-60; PMID:21364280; http://dx.doi.org/10.1172/JCI44855
   PubMed Web of Science ®Google Scholar
• Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010; 16(19):4779-88; PMID:20876793; http://dx.doi.org/10.1158/1078-0432.CCR-10-1818
   PubMed Web of Science ®Google Scholar